Ozygala A, Rokosz-Mierzwa J, Widz P, Skowera P, Wilinski M, Styka B
Cancers (Basel). 2024; 16(23).
PMID: 39682300
PMC: 11640741.
DOI: 10.3390/cancers16234114.
Parciante E, Cumbo C, Anelli L, Zagaria A, Redavid I, Minervini A
Int J Mol Sci. 2023; 24(5).
PMID: 36902299
PMC: 10003372.
DOI: 10.3390/ijms24054860.
Easwar A, Siddon A
Life (Basel). 2021; 11(11).
PMID: 34833034
PMC: 8625510.
DOI: 10.3390/life11111158.
Di Battista V, Bochicchio M, Giordano G, Napolitano M, Lucchesi A
Int J Mol Sci. 2021; 22(2).
PMID: 33429941
PMC: 7827003.
DOI: 10.3390/ijms22020561.
Rizvi Q, Zaidi U, Shahid S, Ahmed S, Shamsi T
Case Rep Hematol. 2019; 2019:1430170.
PMID: 30805227
PMC: 6360597.
DOI: 10.1155/2019/1430170.
Detection and characterization of homozygosity of mutated by copy neutral loss of heterozygosity in myeloproliferative neoplasms among cases with high mutation loads or with progressive disease.
Stengel A, Jeromin S, Haferlach T, Meggendorfer M, Kern W, Haferlach C
Haematologica. 2018; 104(5):e187-e190.
PMID: 30409794
PMC: 6518876.
DOI: 10.3324/haematol.2018.202952.
Targeted deep sequencing in primary myelofibrosis.
Tefferi A, Lasho T, Finke C, Elala Y, Hanson C, Ketterling R
Blood Adv. 2018; 1(2):105-111.
PMID: 29296803
PMC: 5737166.
DOI: 10.1182/bloodadvances.2016000208.
Three Novel Calreticulin Mutations in Two Turkish Patients.
Hancer V, Tokgoz H, Guvenc S, Caliskan U, Buyukdogan M
Turk J Haematol. 2017; 34(4):360-361.
PMID: 28747287
PMC: 5774355.
DOI: 10.4274/tjh.2017.0146.
Coexisting JAK2V617F and CALR Exon 9 Mutation in Essential Thrombocythemia.
Rashid M, Ahmed R, Ahmed S, Nadeem M, Ahmed N, Shamsi T
Indian J Hematol Blood Transfus. 2016; 32(Suppl 1):112-116.
PMID: 27408370
PMC: 4925557.
DOI: 10.1007/s12288-016-0658-y.
Screening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With Thrombocytosis.
Jeong J, Lee H, Seo J, Seo Y, Kim K, Kim M
Ann Lab Med. 2016; 36(4):291-9.
PMID: 27139600
PMC: 4855047.
DOI: 10.3343/alm.2016.36.4.291.
What Do Molecular Tests Add to Prognostic Stratification in MF: Is It Time to Add These to Our Clinical Practice?.
Guglielmelli P, Rotunno G, Pacilli A, Vannucchi A
Curr Hematol Malig Rep. 2015; 10(4):380-7.
PMID: 26431835
DOI: 10.1007/s11899-015-0285-y.
JAK2 V617F, MPL, and CALR Mutations in Korean Patients with Essential Thrombocythemia and Primary Myelofibrosis.
Kim B, Cho Y, Bae M, Jang S, Seo E, Chi H
J Korean Med Sci. 2015; 30(7):882-8.
PMID: 26130950
PMC: 4479941.
DOI: 10.3346/jkms.2015.30.7.882.
MARIMO cells harbor a CALR mutation but are not dependent on JAK2/STAT5 signaling.
Kollmann K, Nangalia J, Warsch W, Quentmeier H, Bench A, Boyd E
Leukemia. 2014; 29(2):494-7.
PMID: 25249012
PMC: 4320290.
DOI: 10.1038/leu.2014.285.
Detection of MPLW515L/K mutations and determination of allele frequencies with a single-tube PCR assay.
Takei H, Morishita S, Araki M, Edahiro Y, Sunami Y, Hironaka Y
PLoS One. 2014; 9(8):e104958.
PMID: 25144224
PMC: 4140728.
DOI: 10.1371/journal.pone.0104958.
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.
Andrikovics H, Krahling T, Balassa K, Halm G, Bors A, Koszarska M
Haematologica. 2014; 99(7):1184-90.
PMID: 24895336
PMC: 4077079.
DOI: 10.3324/haematol.2014.107482.
Analysis of calreticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment.
Fu R, Xuan M, Zhou Y, Sun T, Bai J, Cao Z
Leukemia. 2014; 28(9):1912-4.
PMID: 24732593
DOI: 10.1038/leu.2014.138.
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients.
Guglielmelli P, Lasho T, Rotunno G, Score J, Mannarelli C, Pancrazzi A
Leukemia. 2014; 28(9):1804-10.
PMID: 24549259
DOI: 10.1038/leu.2014.76.
